Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells

Background: Despite recent improvements in therapy, the five-year survival rate for patients with advanced melanoma is poor, mainly due to the development of drug resistance. The aim of the present study was to investigate the mechanisms underlying this phenomenon, applying proteomics and structural...

Descripció completa

Dades bibliogràfiques

Autors principals:	Claudio Tabolacci, Deborah Giordano, Stefania Rossi, Martina Cordella, Daniela D’Arcangelo, Federica Moschella, Stefania D’Atri, Mauro Biffoni, Angelo Facchiano, Francesco Facchiano
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-11-01
Col·lecció:	Molecules
Matèries:	melanoma BRAFi resistance targeted therapy proteomics protein structure dihydrolipoamide dehydrogenase
Accés en línia:	https://www.mdpi.com/1420-3049/27/22/7800
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!